Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Uropathogenic Escherichia coli (UPEC) motility apparatus is a complex, multi-protein nanomachine, primarily composed of the bacterial flagellum, that facilitates movement through the urinary tract (PubMed: 22237503). It consists of three main parts: a basal body that acts as a rotary motor, a universal joint (hook), and a long helical filament made of flagellin (FliC) (UniProt: P06179). This apparatus is essential for UPEC virulence, allowing the bacteria to ascend from the bladder to the kidneys, thereby causing pyelonephritis and potentially entering the bloodstream (PubMed: 15557271). Beyond locomotion, the motility apparatus is involved in chemotaxis, biofilm formation, and initial adhesion to host cells (PubMed: 21930716). Because motility is a key virulence factor, it is a target for "anti-virulence" therapies that aim to disarm the pathogen without exerting the strong selective pressure for resistance associated with traditional antibiotics (PubMed: 30254114). Experimental inhibitors have been designed to target the MotA/MotB stator complex or disrupt the assembly of the flagellar filament (PubMed: 28808611). These strategies focus on reducing the ability of UPEC to colonize and persist within the host environment, representing a shift toward precision medicine in treating infectious diseases.
Inhibition of flagellar motor rotation, disruption of flagellar assembly, or inhibition of flagellin expression (PubMed: 30254114, PubMed: 28808611).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uropathogenic Escherichia coli flagellar apparatus (UPEC flagellum) (UPEC flagellum).